BMY

Bristol-Myers Squibb Company [BMY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BMY Stock Summary

Top 10 Correlated ETFs

BMY


Top 10 Correlated Stocks

BMY


In the News

04:26 29 Mar 2024 BMY

Bristol Myers' bowel disease drug fails to meet main goal in late-stage study

Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.

08:15 29 Mar 2024 BMY

Is Bristol Myers Squibb Stock a Buy?

Bristol Myers is already facing a major patent cliff, but there are more on the horizon. The company is developing and launching important new medicines to replace older ones.

06:56 29 Mar 2024 BMY

Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.

01:57 29 Mar 2024 BMY

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

01:07 29 Mar 2024 BMY

2 More Potential Biotech Buyout Targets

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

06:56 29 Mar 2024 BMY

Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.

08:56 29 Mar 2024 BMY

Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion

Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.

07:07 29 Mar 2024 BMY

Bristol Myers liver cancer treatment meets main goal of late-stage study

Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer.

10:36 29 Mar 2024 BMY

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.

05:06 29 Mar 2024 BMY

US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy

Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's cell therapy as an earlier treatment for a type of blood cancer.

BMY Financial details

Company Rating
Strong Buy
Market Cap
105.01B
Income
8.03B
Revenue
45.01B
Book val./share
14.52
Cash/share
6.06
Dividend
2.31
Dividend %
4.34%
Employees
34.1K
Optionable
Yes
Shortable
Yes
Earnings
25 Apr 2024
P/E
13.45
Forward P/E
9.74
PEG
4.39
P/S
2.39
P/B
3.67
P/C
8.95
P/FCF
8.51
Quick Ratio
1.24
Current Ratio
1.43
Debt / Equity
1.41
LT Debt / Equity
1.29
-
-
EPS (TTM)
3.88
EPS next Y
5.57
EPS next Q
1.72
EPS this Y
30.64%
EPS next Y
43.55%
EPS next 5Y
74.6%
EPS last 5Y
13.95%
Revenue last 5Y
11.47%
Revenue Q/Q
4.66%
EPS Q/Q
-7.45%
-
-
-
-
SMA20
2.99%
SMA50
3.17%
SMA100
-0.78%
Inst Own
60.15%
Inst Trans
0.81%
ROA
8%
ROE
26%
ROC
0.18%
Gross Margin
76%
Oper. Margin
29%
Profit Margin
18%
Payout
59%
Shs Outstand
2.02B
Shs Float
2.02B
-
-
-
-
Target Price
70.55
52W Range
47.58-71.07
52W High
-23.62%
52W Low
+15.38%
RSI
67.21
Rel Volume
0.79
Avg Volume
16.92M
Volume
13.45M
Perf Week
4.69%
Perf Month
10.92%
Perf Quarter
-3.88%
Perf Half Y
-7.36%
-
-
-
-
Beta
0.372
-
-
Volatility
0.86%, 1.33%
Prev Close
1.84%
Price
54.23
Change
2.32%

BMY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
15.3318.8320.8821.5221.75
Net income per share
2.02-3.983.152.953.88
Operating cash flow per share
4.736.227.36.096.7
Free cash flow per share
4.245.896.865.576.11
Cash per share
9.037.017.754.315.94
Book value per share
30.2616.7516.1814.4814.22
Tangible book value per share
-20.39-15.9-12.28-12.3-9.26
Share holders equity per share
30.2616.7516.1814.4814.22
Interest debt per share
28.2723.5121.1319.5620.6
Market cap
109.44B140.06B138.48B154.31B106.16B
Enterprise value
144.64B177.19B170.1B185.91B136.16B
P/E ratio
31.82-15.5719.824.3913.23
Price to sales ratio
4.193.292.993.342.36
POCF ratio
13.579.978.5411.817.66
PFCF ratio
15.1410.539.0912.928.39
P/B Ratio
2.123.73.854.973.61
PTB ratio
2.123.73.854.973.61
EV to sales
5.534.173.674.033.03
Enterprise value over EBITDA
21.9211.968.439.337.1
EV to operating cash flow
17.9312.6110.514.239.82
EV to free cash flow
2013.3211.1715.5610.76
Earnings yield
0.03-0.060.050.040.08
Free cash flow yield
0.070.090.110.080.12
Debt to equity
0.921.371.271.311.41
Debt to assets
0.370.440.420.420.44
Net debt to EBITDA
5.332.511.571.591.56
Current ratio
1.61.581.521.251.43
Interest coverage
8.333.617.628.3814.79
Income quality
2.33-1.562.312.061.72
Dividend Yield
0.020.030.030.030.04
Payout ratio
0.78-0.450.630.730.59
Sales general and administrative to revenue
00000
Research and developement to revenue
0.240.260.220.210.21
Intangibles to total assets
0.670.620.580.590.51
Capex to operating cash flow
-0.1-0.05-0.06-0.09-0.09
Capex to revenue
-0.03-0.02-0.02-0.02-0.03
Capex to depreciation
-0.48-0.07-0.09-0.11-0.12
Stock based compensation to revenue
0.020.020.010.010.01
Graham number
37.0638.7533.863135.23
ROIC
0.040.070.110.120.23
Return on tangible assets
0.08-0.20.150.160.17
Graham Net
-32.22-25.4-20.55-20.9-19.63
Working capital
11.05B11.11B11.39B5.38B9.51B
Tangible asset value
-34.76B-35.91B-27.27B-26.39B-19.17B
Net current asset value
-48.89B-50.41B-40.05B-38.43B-33.9B
Invested capital
0.921.371.271.311.41
Average receivables
6.83B8.09B10.51B13.23B14.6B
Average payables
2.17B2.58B2.83B2.99B3.15B
Average inventory
2.74B3.18B2.08B2.22B2.5B
Days sales outstanding
107.2972.9898.49110.21123.79
Days payables outstanding
110.4884.11108.29109.46111.24
Days of inventory on hand
193.9864.376.9384.2290.87
Receivables turnover
3.453.713.312.95
Payables turnover
3.34.343.373.333.28
Inventory turnover
1.885.684.744.334.02
ROE
0.07-0.240.190.20.27
Capex per share
-0.49-0.33-0.44-0.52-0.58

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
5.415.45.365.335.66
Net income per share
0.961.080.990.940.87
Operating cash flow per share
1.571.410.92.312.1
Free cash flow per share
1.41.280.782.141.93
Cash per share
4.394.424.173.746.06
Book value per share
14.7315.1615.2814.114.52
Tangible book value per share
-12.52-11.11-9.99-10.43-9.46
Share holders equity per share
14.7315.1615.2814.114.52
Interest debt per share
19.4518.8918.8619.2320.61
Market cap
151.67B145.48B133.85B119.39B104.01B
Enterprise value
183.26B175.86B164.66B151.14B134.01B
P/E ratio
18.7516.0816.1415.4814.76
Price to sales ratio
13.312.8311.9210.899.06
POCF ratio
45.8848.9870.9325.1324.46
PFCF ratio
51.2454.0482.2227.0826.52
P/B Ratio
4.884.574.194.123.53
PTB ratio
4.884.574.194.123.53
EV to sales
16.0715.5114.6713.7811.68
Enterprise value over EBITDA
38.8834.5135.5935.8632.31
EV to operating cash flow
55.4359.2187.2631.8131.52
EV to free cash flow
61.9165.33101.1434.2834.17
Earnings yield
0.010.020.020.020.02
Free cash flow yield
0.020.020.010.040.04
Debt to equity
1.311.241.231.351.41
Debt to assets
0.420.420.420.430.44
Net debt to EBITDA
6.75.966.667.537.23
Current ratio
1.251.421.391.181.43
Interest coverage
8.069.8614.7415.055.33
Income quality
1.631.310.912.462.41
Dividend Yield
0.010.010.010.010.01
Payout ratio
0.570.530.580.620.66
Sales general and administrative to revenue
00000
Research and developement to revenue
0.220.20.20.20.22
Intangibles to total assets
0.590.590.570.550.51
Capex to operating cash flow
-0.1-0.09-0.14-0.07-0.08
Capex to revenue
-0.03-0.02-0.02-0.03-0.03
Capex to depreciation
-0.14-0.11-0.11-0.14-0.13
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
17.8319.1718.4517.2416.85
ROIC
0.040.030.060.050.02
Return on tangible assets
0.050.060.050.050.04
Graham Net
-21.27-19.9-19.23-20.21-20.04
Working capital
5.38B8B7.92B4.17B9.51B
Tangible asset value
-26.39B-23.33B-20.91B-21.46B-19.17B
Net current asset value
-38.43B-35.31B-33.39B-34.57B-33.9B
Invested capital
1.311.241.231.351.41
Average receivables
13.59B13.67B14.23B15.35B15.46B
Average payables
2.82B3.12B3.13B2.94B3.04B
Average inventory
2.21B2.47B2.48B2.4B2.55B
Days sales outstanding
109.97106.42120.73128.42119.7
Days payables outstanding
105.51112.0396.04101.03106.85
Days of inventory on hand
81.1891.3773.9887.4987.28
Receivables turnover
0.820.850.750.70.75
Payables turnover
0.850.80.940.890.84
Inventory turnover
1.110.991.221.031.03
ROE
0.070.070.060.070.06
Capex per share
-0.16-0.13-0.12-0.17-0.16

BMY Frequently Asked Questions

What is Bristol-Myers Squibb Company stock symbol ?

Bristol-Myers Squibb Company is a US stock , located in New york of Ny and trading under the symbol BMY

Is Bristol-Myers Squibb Company buy or a sell ?

18 stock analysts have 18 predictions with a medium analyst target price of $73.56. The lowest prediction is $55 and the highest is $92

What is BMY stock prediction ?

With a median analyst target price of $55, 1 stock analysts have made 1 forecasts in last 90 days. $55 is the lowest and $55 is the greatest projection.

What is Bristol-Myers Squibb Company stock quote today ?

Bristol-Myers Squibb Company stock price is $54.23 today.

Is Bristol-Myers Squibb Company stock public?

Yes, Bristol-Myers Squibb Company is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks